ES2183131T3 - Anticuerpos anti-cd18 utilizados contra el ictus cerebral. - Google Patents

Anticuerpos anti-cd18 utilizados contra el ictus cerebral.

Info

Publication number
ES2183131T3
ES2183131T3 ES97903790T ES97903790T ES2183131T3 ES 2183131 T3 ES2183131 T3 ES 2183131T3 ES 97903790 T ES97903790 T ES 97903790T ES 97903790 T ES97903790 T ES 97903790T ES 2183131 T3 ES2183131 T3 ES 2183131T3
Authority
ES
Spain
Prior art keywords
antibodies used
used against
against cerebral
cerebral ictus
ictus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97903790T
Other languages
English (en)
Inventor
Martin M Bednar
Cordell E Gross
G Roger Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Vermont
Genentech Inc
Original Assignee
University of Vermont
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Vermont, Genentech Inc filed Critical University of Vermont
Application granted granted Critical
Publication of ES2183131T3 publication Critical patent/ES2183131T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE UN METODO PARA MEJORAR EL RESULTADO CLINICO EN EL ATAQUE ISQUEMICO FOCAL EN UN MAMIFERO INCREMENTANDO EL FLUJO SANGUINEO CEREBRAL Y/O REDUCIENDO EL TAMAÑO DEL INFARTO, QUE IMPLICA LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UN ANTICUERPO ANTI CD18 AL MAMIFERO, SIN QUE SE HAYA RETIRADO LA OBSTRUCCION ARTERIAL.
ES97903790T 1996-01-23 1997-01-11 Anticuerpos anti-cd18 utilizados contra el ictus cerebral. Expired - Lifetime ES2183131T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58998296A 1996-01-23 1996-01-23

Publications (1)

Publication Number Publication Date
ES2183131T3 true ES2183131T3 (es) 2003-03-16

Family

ID=24360401

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97903790T Expired - Lifetime ES2183131T3 (es) 1996-01-23 1997-01-11 Anticuerpos anti-cd18 utilizados contra el ictus cerebral.

Country Status (13)

Country Link
EP (2) EP0877626B1 (es)
JP (1) JP4864175B2 (es)
AR (1) AR005535A1 (es)
AT (1) ATE222774T1 (es)
AU (1) AU724449B2 (es)
CA (1) CA2242414C (es)
DE (1) DE69714966T2 (es)
DK (1) DK0877626T3 (es)
ES (1) ES2183131T3 (es)
IL (1) IL125255A (es)
PT (1) PT877626E (es)
WO (1) WO1997026912A2 (es)
ZA (1) ZA97257B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
WO2000048681A2 (en) * 1999-02-17 2000-08-24 Genentech, Inc. Co-administration of a thrombolytic and an anti-cd18 antibody
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP2003527439A (ja) 2000-03-17 2003-09-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ１８抗体と抗ｃｃｒ２抗体の混合物を用いる狭窄および再狭窄を抑制する方法
EP1278538A4 (en) * 2000-03-18 2005-05-04 Millennium Pharm Inc ANTIBODIES BINDING TO CD18 AND INHIBITING STENOSE-RELATED DISORDERS
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US6870034B2 (en) 2002-02-05 2005-03-22 Genentech, Inc. Protein purification
US20060234226A1 (en) 2002-04-26 2006-10-19 Fahner Robert L Non-affinity purification of proteins
DK1648940T3 (en) 2003-07-28 2016-08-15 Genentech Inc Reduction of leaching of protein A during protein A affinity chromatography
JP2007513976A (ja) * 2003-12-15 2007-05-31 デンドレオン コーポレイション Ｈｌａ−ｄｒ特異的抗体、組成物、および方法
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
JP5902367B2 (ja) * 2004-06-30 2016-04-13 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 抗体
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
KR101431856B1 (ko) 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
HUE061746T2 (hu) 2007-07-09 2023-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
EP3441402A1 (en) 2007-10-30 2019-02-13 Genentech, Inc. Antibody purification by cation exchange chromatography
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
DK3604324T3 (da) 2008-08-14 2024-04-08 Genentech Inc Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
CN102209554A (zh) 2008-09-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
WO2010074953A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Stirred tank reactor and method
JP2012512244A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
EP2550018B1 (en) 2010-03-22 2019-02-27 F.Hoffmann-La Roche Ag Compositions and methods useful for stabilizing protein-containing formulations
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
BR112012030197A2 (pt) 2010-05-28 2015-09-29 Genentech Inc diminuição do nível de lactato e aumento da produção de poliptídeo por subregulação da expressão de lactato desidrogenase e piruvato desidrogenase cinase.
SI2585045T1 (sl) 2010-06-24 2019-11-29 Hoffmann La Roche Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US20130012689A1 (en) 2011-07-08 2013-01-10 Emd Millipore Corporation Depth Filters For Disposable Biotechnological Processes
ES2697676T3 (es) 2011-12-22 2019-01-25 Hoffmann La Roche Cromatografía de membrana de intercambio iónico
US20140080180A1 (en) 2012-03-27 2014-03-20 Genentech, Inc. Harvest operations for recombinant proteins
JP6254581B2 (ja) 2012-05-18 2017-12-27 ジェネンテック， インコーポレイテッド 高濃度モノクローナル抗体製剤
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
SG11201700097WA (en) 2014-07-09 2017-02-27 Genentech Inc Ph adjustment to improve thaw recovery of cell banks
WO2017172994A1 (en) 2016-03-29 2017-10-05 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
JP7553241B2 (ja) 2016-12-22 2024-09-18 ジェネンテック， インコーポレイテッド 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
KR102870511B1 (ko) 2018-07-03 2025-10-15 브리스톨-마이어스 스큅 컴퍼니 재조합 단백질 생산 방법
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN113993885B (zh) 2019-04-12 2025-04-25 格尔托公司 重组弹性蛋白及其生产
WO2021021973A1 (en) 2019-08-01 2021-02-04 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1069182A1 (en) * 1992-07-16 2001-01-17 Icos Corporation Alleviation of symptoms associated with inflammatory disease states, using antibodies to CD18
AU5732694A (en) * 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18

Also Published As

Publication number Publication date
WO1997026912A2 (en) 1997-07-31
WO1997026912A3 (en) 1997-10-09
EP0877626B1 (en) 2002-08-28
ZA97257B (en) 1998-07-14
EP1297847A2 (en) 2003-04-02
ATE222774T1 (de) 2002-09-15
DE69714966D1 (de) 2002-10-02
AU1827397A (en) 1997-08-20
AU724449B2 (en) 2000-09-21
IL125255A (en) 2002-02-10
EP0877626A2 (en) 1998-11-18
IL125255A0 (en) 1999-03-12
CA2242414A1 (en) 1997-07-31
DE69714966T2 (de) 2003-04-24
PT877626E (pt) 2003-01-31
JP2000517289A (ja) 2000-12-26
CA2242414C (en) 2012-01-03
AR005535A1 (es) 1999-06-23
EP1297847A3 (en) 2003-05-07
DK0877626T3 (da) 2002-12-30
JP4864175B2 (ja) 2012-02-01

Similar Documents

Publication Publication Date Title
ES2183131T3 (es) Anticuerpos anti-cd18 utilizados contra el ictus cerebral.
KR910004187A (ko) 세트랄린을 사용한 조기사정의 치료방법
ES2170126T3 (es) Composiciones cosmeticas espesadas.
KR890004709A (ko) 항원충제로서의 아지트로마이신 및 이의 유도체
AR004790A1 (es) Reduccion del crecimiento del pelo
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
BR9705207A (pt) Anel de vedação metálico para junta tubular.
EA200101089A1 (ru) Новый способ лечения
EP1491183A3 (fr) Utilisation d'un extrait d'au moins un végétal de la famille des Rosacées
DK0625050T3 (da) TGF-BETA til forbedring af regenerering af nervevæv
DE59605848D1 (de) Transparente, schnell freisetzende zubereitungen von nichtsteroidalen analgetica
ES2195151T3 (es) Dispositivo de mejora de aporte o de muestreo de agentes transdermicos.
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
DE69232150D1 (de) Behandlung von Augenhochdruck mit Betablockern und Prostansäurederivaten
DK0665749T3 (da) Sammensætning til behandling af Parkinsons sygdom
EP0793489A4 (en) Compositions for the treatment of skin disorders
EP0610368A4 (en) TREATMENT OF ACNE OR FOLLICULITIS BARBAE.
ES2102424T3 (es) Composicion de eliminacion de tapones queratosicos.
AR247984A1 (es) Metodo para la preparacion de una composicion sinergica que tiene actividad antiplaca o antigingivitis
ECSP941082A (es) Procedimiento para la preparacion de la sal sodica cristalina adhidra de 5- cloro-3 (2-tenoli)-2- oxindol-1 carboxamida
FR2413084A1 (fr) Composition cosmetique pour le demaquillage des yeux
BG102064A (en) Method for increasing the retinal blood circulation
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
DE69325174D1 (de) Ophthalmische zusammensetzungen und verfahren zu ihrer konservierung und anwendung